

# Clearer Horizons

Charting long-term results for Skyrizi in Adult patients with moderate to severe plaque psoriasis



## PRESENTED BY

Jeffrey LaDuca, PhD, MD

Diplomate of the American Board of Dermatology,  
Reflections Dermatology & Psoriasis Center

Dr. LaDuca received a PHD in physiology from SUNY Buffalo Roswell Park and his medical degree from the SUNY Health Science Center at Syracuse, where he also completed an internship in Internal Medicine. His residency in Dermatology was completed at Strong Memorial Hospital in Rochester, New York and he is a member of the AAD and the American Society of Dermatologic Surgery. Currently, he is a Clinical Professor of Dermatology and in private practice at Reflection Dermatology and Psoriasis Center.

## DATE & TIME

Sunday, November 6, 2022

Presentation: 11:30 AM ET

## LOCATION

Woodlands Hotel and Suites

105 Visitor Center Drive

Williamsburg, VA 23185

## INDICATIONS

**Plaque Psoriasis:** SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

**Psoriatic Arthritis:** SKYRIZI is indicated for the treatment of active psoriatic arthritis in adults.

## SAFETY CONSIDERATIONS

SKYRIZI is contraindicated in patients with a history of serious hypersensitivity reaction to risankizumab-rzaa or any of its excipients. Serious hypersensitivity reactions, including anaphylaxis, have been reported with use of SKYRIZI. If a serious hypersensitivity reaction occurs, discontinue SKYRIZI and initiate appropriate therapy immediately. SKYRIZI may increase the risk of infection. Instruct patients to report signs or symptoms of clinically important infection during treatment. Should such an infection occur, discontinue SKYRIZI until infection resolves. Evaluate patients for tuberculosis infection prior to initiating treatment with SKYRIZI. Avoid use of live vaccines in SKYRIZI patients.

Please see additional Important Safety Information on next page.

Please see accompanying full Prescribing Information or visit [www.rxabbvie.com/pdf/skyrizi\\_pi.pdf](http://www.rxabbvie.com/pdf/skyrizi_pi.pdf).

abbvie

©2022 AbbVie Inc. North Chicago, IL 60064  
US-SKZD-220051 January 2022

  
**Skyrizi**<sup>®</sup>  
risankizumab-rzaa

## IMPORTANT SAFETY INFORMATION

### Hypersensitivity Reactions

SKYRIZI® (risankizumab-rzaa) is contraindicated in patients with a history of serious hypersensitivity reaction to risankizumab-rzaa or any of the excipients. Serious hypersensitivity reactions, including anaphylaxis, have been reported with the use of SKYRIZI. If a serious hypersensitivity reaction occurs, discontinue SKYRIZI and initiate appropriate therapy immediately.

### Infection

SKYRIZI may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated.

In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing SKYRIZI. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, closely monitor and discontinue SKYRIZI until the infection resolves.

### Tuberculosis (TB)

Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.

### Administration of Vaccines

Avoid use of live vaccines in patients treated with SKYRIZI. Medications that interact with the immune system may increase the risk of infection following administration of live vaccines. Prior to initiating SKYRIZI, complete all age appropriate vaccinations according to current immunization guidelines.

### Adverse Reactions

Most common ( $\geq 1\%$ ) adverse reactions associated with SKYRIZI include upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections.

In psoriatic arthritis phase 3 trials, the incidence of hepatic events was higher with SKYRIZI compared to placebo.

SKYRIZI is available in a 150 mg/mL prefilled syringe and pen.

**Please see accompanying full Prescribing Information or visit [www.rxabbvie.com/pdf/skyrizi\\_pi.pdf](http://www.rxabbvie.com/pdf/skyrizi_pi.pdf).**



**Skyrizi**<sup>®</sup>  
risankizumab-rzaa